• Markus Böbel, Stefanie Joos, and Christian Förster.
• Praxis für Allgemeinmedizin Dr. Böbel, Reutlingen.
• Dtsch. Med. Wochenschr. 2022 Apr 1; 147 (9): 558-563.

BackgroundNeutralizing monoclonal antibodies (mAB) against SARS-CoV-2 reduce the severity of COVID-19 in patients with risk factors. Early administration at the onset of infection is critical for their efficacy. At this early stage of the disease, family physicians are often the first help for patients and thus central to the further course of the disease. To date, however, mAB have only rarely been used in general practice. The purpose of this case series is to demonstrate that the administration of mAB is safely feasible in the primary care setting.Case ReportWe report seven cases at risk for severe COVID-19. Two of them were not vaccinated, five had drug induced immunosuppression, and one patient was at high risk because of trisomy-21. All patients were successfully treated with the mAB Sotrovimab in a GP's practice in January/ February 2022. Two patients were treated making a house call. Based on the cases, clinical information and a hands-on handling of this therapy are described.ConclusionsNeutralizing mAB can be administered safely and with manageable effort in primary care setting and can help prevent a severe course and hospitalization in patients with COVID-19 and risk factors.Thieme. All rights reserved.

17 keywords...

hide…